Trimeris, searching for additional money to fund further development and commercialzation of its new AIDS drug Fuzeon, priced its new stock offering at $45.25 this morning.

The company is offering 2.4 million shares of common stock. Underwriters have been granted the option to purchase up to an additional 360,000 shares.

Trimeris (Nasdaq: TRMS) stock closed at $45.81 on Thursday. It was up $1.66, or 3.8 percent, for the day.

According to a statement, Trimeris hopes to raise up tp $117.9 million with the sale.

Morgan Stanley & Co. and Goldman, Sachs & Co. are among the underwriters. Co-managers are Leham Brothers and Banc of America Securities.